Condensed Consolidated Interim Financial Statements

For the nine months ended December 31, 2024 and 2023 (Unaudited – Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

Condensed Consolidated Interim Statements of Financial Position

(Unaudited – Presented in Canadian Dollars)

		December 31,	March 31,
AS AT	Note	2024	2024
ASSETS			
Current assets			
Cash		\$ 111,593	\$ 56,596
Accounts receivable		122,650	107,362
Loans receivable – current	6	37,891	81,686
Prepaid expenses		12,161	7,490
		284,295	253,134
Loans receivable	6	50,660	118,780
Property, equipment, and right-of-use assets	7	9,402	12,021
Intangible assets	8	673,020	826,365
Goodwill	4	1,399,824	1,399,824
Total assets		\$ 2,417,201	\$ 2,610,124
LIABILITIES AND SHAREHOLDERS' DEFICIENCY			
Current liabilities			
Accounts payable	13	\$ 1,520,248	\$ 1,294,873
Accrued liabilities		705,482	666,707
Interest payable	13	211,891	145,528
Convertible debentures	9,12	825,382	794,287
Loans payable	10,12	974,533	751,723
		4,237,536	3,653,118
Deferred income tax liability	4	223,416	223,416
Loans payable	10	-	430
Total liabilities		4,460,952	3,876,964
Shareholders' deficiency			
Share capital	12	20,557,694	19,702,594
Shares issuable	12	67,800	67,800
Subscriptions received in advance		80,000	37,000
Equity component of convertible debentures	9	63,974	63,974
Reserves	12	1,644,413	1,374,292
Accumulated deficit		(24,457,632)	(22,475,500)
Total shareholders' deficiency		(2,043,751)	(1,266,840)
Total liabilities and shareholders' deficiency		\$ 2,417,201	\$ 2,610,124

Nature of operations and going concern (Note 1); Events after the reporting period (Note 16)

"Karim Nanji"	Director	"Farhan Abbas"	Director

Approved on behalf of the Board of Directors on February 28, 2025

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited – Presented in Canadian Dollars)

		For the three Decer				For the nine mon Decembe			
		2024		2023		2024		2023	
Revenues									
Verification fees	\$	302,930	,	\$ 228,355	\$	919,379	\$	707,304	
Loan interest revenue (Note 6)	Ф	8,257		25,011	φ	35,877	φ	91,414	
Subscription fees		0,237		8,089		33,677		57,418	
Marketing service fees		-		13,000		2,000		79,530	
Service fees and other		-		(229)		2,000			
Total Revenues		311,187		274,226		957,256		(177) 935,489	
		,		,		,		,	
Operating expenses									
Administration costs		77,858		26,398		161,823		136,192	
Amortization (Notes 7 and 8) Bad debts expense and allowance for loan		51,985		37,744		155,962		119,482	
impairment		7,837		(17,143)		31,131		31,974	
Contractor Services (Note 13)		140,478		111,848		417,713		501,236	
Investor relations		37,410		21,860		96,722		76,555	
Marketing		24,270		53,043		86,078		196,667	
Professional fees		48,831		52,775		119,933		173,091	
Salary and benefits (Note 13)		315,989		317,310		937,924		1,030,904	
Share based payments (Notes 12 and 13)		95,208		84,497		347,622		151,371	
Software and platform technology services		128,323		113,496		407,495		439,946	
Transfer agent and filing fees		5,502		9,136		17,441		39,282	
Total operating expenses		933,691		810,964		2,779,844		2,896,700	
Finance costs		40.40		40.0=0				4.0.00	
Interest expense (Notes 9, 10 and 13)		48,692		48,073		137,971		143,291	
Accretion expense (Notes 9 and 12)		-		15,010		33,095		13,100	
Total finance costs		48,692		63,083		171,066		156,391	
Other income (expenses)									
Loss on settlement of interest payable (Note 9)		-		-		-		(7,140)	
Gain on settlement of accounts payable		-		(10,000)		-		30,034	
Impairment loss on intangible asset (Note 8)		-		25,000		-		(89,419)	
Gain on settlement of bonds (Note 11) Gain (loss) on settlement of earn-out provision		-		-		-		2,940,648	
(Note 4)		-		-		-		(2,148)	
Write-off of accounts (receivable) payable		(459)				11,522			
Total other income (expenses)		(459)		15,000		11,522		2,871,975	
Net income (loss) and comprehensive income									
(loss)	\$	(671,655)	\$	(584,821)	\$	(1,982,132)	\$	754,373	
Basic and diluted income (loss) per common share	\$	(0.00)	\$	(0.00)	\$	(0.01)	\$	(0.00)	
Weighted average number of shares outstanding – basic and diluted		211,301,744		183,430,237		207,112,948		162,565,689	

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Changes in Shareholders' Deficiency (Unaudited – Presented in Canadian Dollars)

	Share Ca	apital								
	Number of shares	Amount	Subscriptions received in advance	Shares issuable		ck option warrant reserves	of c	Equity component convertible debentures	Deficit	Total
Balance, December 31, 2022	121,508,618	\$ 14,601,337	\$ -	\$ 67,800	\$ 1	,158,521	\$	71,079	\$(21,541,659)	\$ (5,642,922)
Disposal of subsidiaries	-	(600)	-	-		-		-	-	(600)
Shares issued under RSU plan (Note 12)	600,000	49,500	-	-		(49,500)		-	-	-
Shares issued for options exercised (Note 12)	600,000	30,000	-	-		-		-	-	30,000
Subscriptions received in advance (Note 12) Shares issued for private placement (including	-	-	220,000	-		-		-	-	220,000
agent shares) (Note 12)	24,034,970	1,364,760	(220,000)	-		(7,860)		-	-	1,136,900
Shares issued for bond settlements (Note 12) Shares issued for settlement of accounts payable	44,298,850	2,834,572	-	-		-		-	-	2,834,572
(Note 12)	1,835,893	97,035	-	-		-		-	-	97,035
Shares issued for earn-out provision (Note 12) Shares issued for settlement of interest payable	2,907,011	683,148	-	-		-		-	-	683,148
(Note 12)	714,027	42,842	-	-		-		-	-	42,842
Share-based payments (Note 12) Equity component of convertible debentures (Note	-	-	-	-		273,131		-	-	273,131
9)	-	-	-	-		-		(7,105)	71,079	63,974
Net loss for the period	-	-	-	 -		-		-	(1,004,920)	(1,004,920)
Balance, March 31, 2024	196,499,369	\$ 19,702,594	\$ -	\$ 67,800	\$ 1	,374,292	\$	63,974	\$(22,475,500)	\$ (1,266,840)
Shares issued under RSU plan (Note 12) Shares issued for convertible debentures	1,600,000	77,500	-	-		(77,500)		-	-	-
redemption	28,571	2,000	-	-		-		-	-	2,000
Finder's fees	-	(15,400)	-	-		-		-	-	(15,400)
Subscriptions received in advance Shares issued for private placement (including	-	-	80,000	-		-		-	-	80,000
agent shares) (Note 12)	15,820,000	791,000	-	-		-		-	-	791,000
Share-based payments (Note 12)	-	-	-	-		347,621		-	-	347,621
Net loss for the period				-		-		-	(1,982,132)	(1,982,132)
Balance, December 31, 2024	213,947,940	20,557,694	80,000	67,800	1	,644,413		63,974	(24,457,632)	(2,043,751)

The accompany notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Cash Flows

(Unaudited – Presented in Canadian Dollars)

For the nine months ended December 31,	Note	2024	2023
CASH FROM OPERATING ACTIVITIES			
Net income (loss) for the period		\$ (1,982,132)	\$ 754,373
Items not affecting cash:		, , ,	,
Amortization	7,8	155,964	119,482
Accrued interest on bonds payable		, -	1,450
Share based payments	13	347,621	151,371
Accretion on convertible debentures	9	33,095	13,099
Impairment loss on intangible asset		-	89,419
Gain on settlement of accounts payable		-	(30,034)
Loss on settlement of interest payable		-	-
Gain on settlement of bonds	12	_	(2,940,648)
Write-off of accounts (receivable) payable		11,522	-
(Gain) loss on settlement of earn-out provision	4	, -	2,148
Changes in non-cash working capital items:			,
Accounts receivables		(15,288)	57,947
Interest receivable		(7,364)	(1,762)
Loans receivable		119,279	233,152
Prepaid expenses		(4,671)	39,687
Unearned revenue		-	(44,277)
Accounts payable		213,853	181,708
Accrued liabilities		38,775	202,941
Interest payable		66,363	126,232
Net cash used in operating activities		(1,022,983)	(1,036,572)
CACH EDOM INVECTING A CENTREE			
CASH FROM INVESTING ACTIVITIES	7		
Acquisition of property, equipment, and right-of-use asset	/	-	25.000
(Acquisition) refund of Accumulate.ai assets		-	25,000
Net cash used in investing activities			25,000
CASH FROM FINANCING ACTIVITIES			
Common shares issued, net of share issuance costs		775,600	576,750
Subscriptions received in advance		80,000	165,000
Proceeds from loans received (Note 10)	10	296,250	308,261
Shares Issuable		-	30,000
Payment of loans payable (Note 10)	10	(73,870)	(7,204)
Net cash generated by financing activities		1,077,980	1,072,807
Change in cash during the period		54,997	61,235
Cash, beginning of the period		56,596	88,896
Cash, end of the period		\$ 111,593	\$ 150,131
Interest received		\$ 23,246	\$ 57,791
Interest paid *		\$ 42,405	\$ 949

^{*} Includes interest paid on bonds, convertible debentures and loans

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Supplemental cash flow information (Note 16)

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

1. NATURE OF OPERATIONS

Inverite Insights Inc. (Formerly Marble Financial Inc. "Inverite", collectively with its subsidiaries, the "Company") was incorporated. under the Business Corporation Act (British Columbia) on July 7, 2015. The head office of the Company is located at Suite 404-999 Canada Place, Vancouver, British Columbia, V6C 3E2. Inverite's common shares are listed for trading on the Canadian Securities Exchange ("CSE") under the symbol "INVR," quoted on the OTC Pink market under the symbol "INVRF" and on the Frankfurt Stock Exchange under the symbol "2V00".

On January 25, 2024, Marble Financial Inc. has changed its name to Inverite Insights Inc. to better reflect the primary business of the company.

In December 2023, the Company changed the fiscal year end to March 31, 2024.

The Company's primary business activity is an AI-driven software provider specializing in real-time financial data which empowers business lenders and financial institutions to transact more effectively and efficiently with consumers seeking credit through innovative solutions for data enrichment, identify-KYC, risk management and compliance. Inverite Verification Inc., the Company's wholly owned subsidiary, operates as a cloud-based transactional and Risk Model as a Service ("RMaaS") platform and offers Open Banking and consumer-directed finance solutions, consisting of banking verification solutions to the financial services industry for income verification, credit decisioning, fraud reduction, and know-your client/anti-money laundering purposes. Additionally, Inverite Insights operates on a SaaS model, charging merchants a monthly platform access fee. The Company has offered solutions to underbanked consumers through its MyMarble Platform, which is a consumer facing user interface ("UI") platform designed to provide consumers access to personalized granular solutions in the areas of, budgeting, credit insights, financial literacy and education, combined savings and credit rebuilding tool and a credit improvement subscription program. The Company has also offered marketing services to find qualified underbanked consumers interested in purchasing a vehicle for its clients focussed in auto sales, through its wholly owned subsidiary, Accumulate.ai Software Ltd. For the underbanked consumers that fall short on achieving credit, the Company's proprietary Point Deduction Technology ("PDT") provides customers with a prescriptive ability to understand, build and maintain a positive credit report and credit score, gain specific and unique budgetary and credit insights with access to financial education and literacy. During the period ended March 31, 2024, the Company suspended allocating resources for MyMarble and Accumulate.ai, resulting in the discontinuation these operations. The Company continues to prioritize resources towards Inverite Verification on a go forward basis and changes revenue segment to Inverite Verification.

These consolidated financial statements have been prepared on the basis of a going concern which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2024 the Company had a working capital deficit of \$3,953,241 (March 31, 2024 – \$3,399,984), a shareholders' deficiency of \$2,043,751 (March 31, 2024 – \$1,266,840) and an accumulated deficit of \$24,457,632 (March 31, 2024 – \$22,475,500) and therefore will need ongoing funding to continue its operations. There is no assurance that additional funding will be available on a timely basis or on terms acceptable to the Company. If the Company is unable to obtain sufficient funding, the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of the going concern accounting principle will be in significant doubt. These condensed consolidated interim financial statements do not reflect the adjustments or reclassification which would be necessary if the Company were unable to continue its operations in the normal course of business.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

2. BASIS OF PRESENTATION

Statement of compliance

The Company prepared these condensed consolidated interim financial statements in accordance with International Accounting Standard 34 ("IAS 34") Interim Financial Reporting. These condensed consolidated interim financial statements were approved by the Board of Directors and authorized for issue on February 26, 2024. The accounting policies and methods of computation applied by the Company in these condensed consolidated interim financial statements are the same as those applied in the Company's annual consolidated financial statements for the year ended March 31, 2024. The condensed consolidated interim financial statements do not include all of the information required for full annual financial statements.

Basis of measurement

These condensed consolidated interim financial statements are prepared on the historical cost basis, except for certain items recorded at fair value. These condensed consolidated interim financial statements are presented in Canadian dollars, which is the Company's functional currency.

Basis of consolidation

The Company's consolidated financial statements include Inverite and its wholly owned subsidiaries as follows:

Company	Place of Incorporation	Effective Interest
Inverite Verification Inc. ("Inverite Verification")	British Columbia	100%
Score-Up Inc. ("Score-Up")	Ontario	100%
TPFM The Phoenix Fund Management Ltd. ("TPFM")	British Columbia	100%

On September 1, 2022, Accumulate.ai was incorporated under the Canada Business Corporations Act and extraprovincially registered under the Business Corporations Act (British Columbia) in British Columbia on September 2, 2022. Accumulate.ai was created for the purposes of acquiring certain assets related to a marketing service business (see Note 5).

On February 29, 2024, the Company as a part of its corporate restructuring and focus on its Inverite Verification platform moving forward, voluntarily dissolved Accumulate.ai Software Ltd., Credit Meds Corp., 1301771 B.C. Ltd., and TPF The Pheonix Fund Inc.

Control is achieved where the Company has power over an entity, has exposure or rights to variable returns from its involvement with the entity and has the ability to use its power over the entity to affect the amount of the investor's returns. Subsidiaries are included in the consolidated financial statements from the date control commences until the date control ceases. All inter-company balances, transactions, revenues and expenses have been eliminated on consolidation.

Comparative Figures

The presentation of comparative figures on the condensed consolidated interim statements of income (loss) and comprehensive income (loss) has been conformed to the presentation used in current year.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

3. USE OF ESTIMATES AND JUDGMENTS

The preparation of these consolidated financial statements requires management to make estimates and judgments and to form assumptions that affect the reported amounts and other disclosures in these consolidated financial statements. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. The results of these assumptions form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

The estimates and underlying assumptions are reviewed on an ongoing basis. Changes to accounting estimates are recognized in the period in which the estimate is revised and all future periods which are affected by the change in estimate. The principal areas where critical estimates and judgments have been applied are described below:

Impairment losses on loans receivable

The Company regularly reviews its loans receivable for potential impairment. In determining whether an impairment loss should be recorded in profit or loss, the Company considers whether there is any observable data indicating that an increase in the credit risk or a decrease in the estimated future cash flows from a loan has occurred. This evidence may include observable data indicating that there has been an adverse change in the payment status of the borrower. Management uses estimates based on valuation techniques including the discounted cash flow model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of estimation is required. The estimates include future market interest rates.

Impairment of intangible assets and goodwill

Intangible assets which are available for use and have a definite useful life are assessed for indicators of impairment at the end of each reporting period. If indicators of impairment exist, the Company will test those intangible assets for impairment. The Company tests intangible assets with an indefinite useful life, intangible assets which are not yet ready for use, and goodwill on an annual basis. Significant judgment is required in determining the useful lives and recoverable amounts of these assets, evaluating the appropriate allocation of assets to cash-generating units, and assessing whether certain events or circumstances constitute objective evidence of impairment. Estimates of the recoverable amounts of these assets rely on certain inputs and assumptions, including future cash flows and discount rates, and may be sensitive to changes in these inputs and assumptions. Future cash flows are based on revenue projections and allocated costs which are estimated based on historical and forecast results and business initiatives. Discount rates are based on an assessment of current market assessments of the time value of money and the risks specific to the asset or cash-generating unit.

Income taxes

Income tax expenses recorded in these consolidated financial statements are not final until tax returns are filed and accepted by taxation authorities. Therefore, results of operations in future reporting periods may be affected by the difference between the income tax expense estimates and the final tax assessments. Estimation of income taxes includes evaluating the recoverability of deferred tax assets based on an assessment of the ability to use the underlying future tax deductions against future taxable income. The assessment is based on enacted tax acts and estimates of future taxable income.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

3. USE OF ESTIMATES AND JUDGMENTS (continued)

Business combinations

Management determines whether assets acquired, and liabilities assumed constitute a business. A business consists of inputs and processes applied to those inputs that have the ability to create outputs. On April 12, 2021, Inverite completed the acquisition of 100% of the shares of Inverite (Note 4) which was accounted for as a business combination at fair value in accordance with IFRS 3, "Business Combinations" as the operations of Inverite meet the definition of a business. The acquired assets and assumed liabilities were adjusted to their fair values assigned through completion of a purchase price allocation, as described in Note 4. On October 18, 2022, Accumulate.ai completed the acquisition of certain assets related to a marketing services business (Note 5) which was accounted for as a business combination at fair value in accordance with IFRS 3, "Business Combinations" as the operations of the assets met the definition of a business. The purchase price allocation process resulting from a business combination requires management to estimate the fair value of identifiable assets acquired including intangible assets and liabilities assumed. The valuations are closely linked to the assumptions used by management on the future performance of the related assets and the discount rates applied.

4. ACQUISITION OF INVERITE VERIFICATION

On April 12, 2021, the Company acquired all of the issued and outstanding shares of Inverite Verification for a purchase price of \$1,460,000 plus an earn out provision of up to \$2,500,000 which will be based on a multiple of annual incremental revenues ("AIR") of Inverite Verification over the two consecutive one-year periods following the closing date, payable in cash or common shares at the option of the Company. The effective price of any common shares issued in satisfaction of the payment of any portion of the earn-out amount will be the greater of (i) the volume weighted average price of the common shares of the Company for the 10 consecutive trading days preceding the last day of the applicable earn-out period, and (ii) closing share price on the last trading day prior to the closing date, which was \$0.235 per share.

The transaction was accounted for as a business combination and, as the operations of Inverite Verification meet the definition of a business, all transaction costs were expensed. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets will represent the sales and growth potential of Inverite Verification.

The fair value of the consideration transferred has been allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition as follows:

Purchase price consideration	
Cash	\$ 1,460,000
Estimated fair value of earn-out provision	982,000
	\$ 2,442,000
Assets acquired and liabilities assumed	
Working capital	\$ 37,378
Loan payable	(40,000)
Deferred income tax liability	(386,432)
Intangible assets	1,431,230
Goodwill	1,399,824
	\$ 2,442,000

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

4. ACQUISITION OF INVERITE VERIFICATION (continued)

A reconciliation of the earn-out provision subsequent to the date of acquisition is as follows:

Earn-out provision, December 31, 2021	\$ 982,000
Settled through the issue of 1,577,000 shares (Note 14)	(370,595)
Increase in earn out provision	69,595
Earn-out provision, December 31, 2022	681,000
Increase in earn out provision	2,148
Settled through the issue of 2,907,011 shares (Note 14)	(683,148)
Earn-out provision, December 31, 2023	\$ -

5. ACQUISITION OF ACCUMULATE.AI ASSETS

On October 18, 2022, Accumulate.ai Software Ltd., a subsidiary of the Company, completed the acquisition of certain assets related to a marketing services business for consideration of up to CDN\$550,000. The purchase price payable is comprised of: (i) a cash payment of \$125,000 paid on closing, of which \$25,000 was paid into escrow, and (ii) an earn-out of up to \$425,000 equal to 33-1/3% of the net income of the acquired business realized during the eight successive quarterly financial reporting periods following the closing date. On October 19, 2023, the Company entered into an agreement with the vendor whereby the vendor agreed to return the \$25,000 held in escrow back to the Company.

Subject to regulatory approval, the earn-out will be paid in the form of common shares of Inverite issued from treasury, calculated based on the volume weighted average closing trading price ("VWAP") of Inverite common shares on the Canadian Securities Exchange for the five prior trading days ending three trading days prior to the end of each financial quarter. The earn-out shall cease and be of no further effect if the net income of the business is negative for two successive fiscal quarters during the earn-out period. As at December 31, 2023, the Accumulate business model has been discontinued, the subsidiary has been dissolved, and the earn-out provision had ceased as net income was negative for two successive fiscal quarters.

The transaction was accounted for as a business combination and, as the assets and operations acquired meet the definition of a business, all transaction costs were expensed.

The fair value of the consideration transferred has been allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition as follows:

Purchase price consideration	
Cash	\$ 125,000
A	
Assets acquired and liabilities assumed	
Intangible assets	\$ 125,000

During the period ended March 31, 2024, the Company impaired the carrying values for the Accumulate ai intangible assets to \$nil and recorded an impairment loss in the aggregate amount of \$89,419.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

6. LOANS RECEIVABLE

The Company previously provided loans to consumer debtors who met the Company's evaluation criteria and who would use the borrowed funds to settle debts under formal restructuring plans (Consumer Proposals) agreed upon by the creditors of the consumer debtors as well as loans provided to consumers pursuant the Company's Boost loan program. The majority of the loans issued to consumer debtors and Boost loans were unsecured. The debt restructuring loans receivable generally bear interest between 18.99% and 24.99% and mature between three and seven years from the date of issuance. Boost loans are 12-month interest free installments loans used to finance a 12-month subscription to the Company's MyMarble Premium subscription product. During the period ended March 31, 2024, the Company discontinued MyMarble subscription services and Boost loans.

Loans receivable and interest receivable

	Dec	cember 31, 2024	March 31, 2024
Unsecured personal loans	\$	161,568	\$ 316,599
Less: allowance for loan impairment		(73,017)	(116,133)
Total loans and interest receivable, net of allowance for loan impairment		88,551	200,466
Interest receivable, current portion		(7,364)	(13,295)
Loans receivable, current portion		(30,527)	(68,391)
Loans receivable – non-curent portion	\$	50,600	\$ 118,780

Reconciliation of allowance for loan impairment

	Dece	December 31,		March 31,
		2024		2024
Balance, beginning of the period / year	\$	151,402	\$	151,402
Change in provision for impairment losses		(78,385)		(35,269)
Balance, end of the period	\$	73,017	\$	116,133

The Company makes estimates of expected loan receivable impairment losses based on the probability of credit losses occurring and considering the delinquency of the loans outstanding, past experiences regarding losses, and an ongoing assessment of the market and of individual consumer debtors. The Company also categorizes its loans by the number of days the loan payments are past due and estimates the probability of credit losses within these categories. The allowance for credit losses is maintained at a level that the Company considers adequate to absorb credit-related losses over the next 12 months, where loan payments are current and credit risk has not significantly increased, and over the lifetime of the loan, where loan payments are past due or credit risk has significantly increased.

The allowance for credit losses of \$73,017 represents 45.2% of the Company's outstanding loans receivable balance, inclusive of interest receivable, as at December 31, 2024 (March 31, 2024 – 36.68%). The increase in allowance for credit losses as a percentage of the loan portfolio is due to an increase in the proportion of loans where payments are past due and a change in the expectation of loan repayments partly as a result of factors that impact on the financial condition of the Company's consumer debtors.

A loan receivable is considered past due when a consumer debtor has not made a payment by the contractual due date and written off when the consumer debtor has declared bankruptcy or applied for a consumer protection, or the Company has sent the loan receivable to an external collection agency for collections. During the nine-month period ended December 31, 2024, the Company wrote off \$1,035 (2023 – recovered \$78,433) in loans and interest receivable.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

6. LOANS RECEIVABLE (continued)

Loans receivable past due

The following tables present the carrying values of loans that are past due but which have not been written off because: (i) the Company is in continuous contact with the consumer debtor and the Company and the consumer debtor have established an appropriate repayment plan, or (ii) the loan receivable is secured and the fair value of the collateral is sufficient to cover the carrying value of the loan receivable.

December 31, 2024	30-60 days	61-90 days	O	ver 90 days	Total
Personal loans	\$ 920	\$ 6,846	\$	139,289	\$ 147,055
Total past due	\$ 920	\$ 6,846	\$	139,289	\$ 147,055

March 31, 2024	30-60 days	61-90 days	(Over 90 days	Total
Personal loans	\$ 12,194	\$ 4,251	\$	129,466	\$ 145,911
Total past due	\$ 12,194	\$ 4,251	\$	129,466	\$ 145,911

Contractual maturities

The contractual maturities of loans receivable as at December 31, 2024 are as follows:

	Un	der 1 year	1-5 years	Ove	r 5 years	Total
Unsecured personal loans	\$	72,662	\$ 86,421	\$	2,484	\$ 161,568
Less: allowance for credit losses						(73,017)
Loans and interest receivable, net	\$	72,662	\$ 86,421	\$	2,484	\$ 88,551

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

7. PROPERTY, EQUIPMENT, AND RIGHT-OF-USE ASSETS

	_		a		 1
	<u> </u>	urniture	Со	mputers	Total
Cost					
December 31, 2022	\$	35,361	\$	43,994	\$ 79,355
Additions		-		-	-
March 31, 2024	\$	35,361	\$	43,994	\$ 79,355
Additions		-		-	-
December 31, 2024	\$	35,361	\$	43,994	\$ 79,355
Accumulated Amortization					
December 31, 2022	\$	23,482	\$	34,036	\$ 57,518
Amortization		2,970		6,847	9,817
March 31, 2024	\$	26,452	\$	40,883	\$ 67,335
Amortization		1,337		1,281	2,618
December 31, 2024	\$	27,789	\$	42,164	\$ 69,953
Carrying values					
March 31, 2024	\$	8,909	\$	3,111	\$ 12,020
December 31, 2024	\$	7,572	\$	1,830	\$ 9,402

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

8. INTANGIBLE ASSETS

		Inverite Verification platform		Total
Cost				
December 31, 2022	\$	1,431,230	\$	1,431,230
Acquisition		-		<u> </u>
March 31, 2024 Acquisition	\$	1,431,230	\$	1,431,230
Acquisition				<u>-</u>
December 31, 2024	\$	1,431,230	\$	1,431,230
Amortization Provision and Impairment Losses				
December 31, 2022	\$	244,502	\$	244,502
Amortization		360,363		360,363
March 31, 2024 Amortization	\$	604,865 153,346	\$	604,865 153,346
December 31, 2024	\$	758,211	\$	758,211
Carrying values	φ	926.265	¢	926.265
March 31, 2024	\$	826,365	\$	826,365
December 31, 2024	\$	673,019	\$	673,019

Due to the uncertainty in the timing and amount of future cash flows from operations and unobservable market values for comparable intellectual property, the Company wrote down the carrying values for the Accumulate ai assets to \$nil and recorded an impairment loss in the aggregate amount of \$89,419 during the period ended March 31, 2024. The recoverable amount was determined on the basis of value in use, using a discount rate of 21.62%. On October 19, 2023, Inverite and its wholly owned subsidiary, Accumulate.ai Software, entered into an agreement with the vendor of the Accumulate.ai assets, whereby the vendor agreed to return the \$25,000 held in escrow back to the Company.

During the period ended March 31, 2024, the Company changed its business name to Inverite Insights Inc. and wrote down the trademark's intangible value to \$Nil. Furthermore, the Company revised the useful economic life of the Inverite Verification platform assets, comprising acquired software and related technological processes, from 10 years to 7 years. This adjustment reflects management's assessment of the technology's efficiency and usage in light of the Company's evolving activities. As a result, the Company recorded accelerated depreciation of \$360,363 for the period ended March 31, 2024.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

9. CONVERTIBLE DEBENTURES

On April 7, 2021, the Company closed a non-brokered private placement of unsecured convertible debentures (the "Debentures") with an aggregate principal amount of \$1,303,000. The Debentures had a 15-month term from the date of issuance and accrue simple interest at a rate of 10% per annum, payable semi-annually. The principal amount of the Debentures and all accrued but unpaid interest are convertible, at the option of the holder, into units at a price of \$0.30 per unit. Each unit is comprised of one common share and one-half of one share purchase warrant, with a whole warrant exercisable to purchase a common share at a price of \$0.45 until 21 months after the closing date. The Company may force conversion of the principal amount into units at \$0.30 per unit if at any time after four months and a day after the closing date, the common shares have traded or closed on the CSE at \$0.60 or more for 10 consecutive trading days. In connection with the private placement, the Company incurred an aggregate of \$40,150 in finder fees and issued an aggregate of 133,832 finder warrants with an estimated fair value of \$9,641 using the Black-Scholes pricing model using the following weighted average assumptions:

Risk-free rate	0.26%
Expected life of finder warrants	1.25 years
Annualized volatility	80%
Dividend rate	0%

Each finder warrant is exercisable into one common share at a price of \$0.30 for a period of 15 months following closing. (See Note 14).

In August 2021, the Company entered into amending agreements with the Debentures holders to extend the maturity date from July 7, 2022 to December 31, 2022, and in respect of the underlying warrants issuable on conversion to extend their expiry date from January 7, 2023 to June 30, 2023. On November 28, 2022, \$500,000 Debentures, plus outstanding accrued interest thereon, were used as payment to settle subscriptions in a non-brokered private placement. \$44,259 was transferred from equity portion of convertible debentures to deficit. See Notes 14 and 15. A loss on settlement of \$6,870 was recorded.

On February 21, 2023 the Company entered into agreements with convertible debenture holders to settle convertible debentures with a principal amount of \$803,000 which matured on December 31, 2022 through the issuance of new convertible debentures. \$71,079 was transferred from equity portion of convertible debentures to deficit as a result. On March 6, 2023, Inverite issued an aggregate of \$814,440 principal amount of new convertible debentures (the "2023 Debentures") in exchange for the full settlement and discharge owing on the \$803,000 principal amount of convertible debentures that matured on December 31, 2022 plus unpaid accrued interest thereon of \$11,440. The 2023 Debentures mature on July 31, 2023 and bear simple interest at a rate of 10% payable on the maturity date. The principal amount of the 2023 Debentures were convertible, at the option of the holder, into common shares of Inverite at a price of \$0.10 per share, subject to a forced conversion provision.

On August 14, 2023, the Company settled accrued interest payable of \$35,701 to July 31, 2023 related to the 2023 Debentures through the issuance of 714,027 common shares at \$0.06 per share. A loss on settlement of \$7,140 was recorded. On September 28, 2023, the Company entered into new agreements with the convertible debenture holders to settle the 2023 Debentures with a principal amount of \$814,440 that had matured on July 31, 2023, through the issuance of new convertible debentures. In exchange for the full settlement and discharge of the \$814,440 principal amount of 2023 Debentures, plus unpaid accrued interest of \$12,942, the Company issued an aggregate of \$827,382 principal amount of new convertible debentures on September 28, 2023 (referred to as the "2024 Debentures"). The 2024 Debentures matured on September 28, 2024, and they bear simple interest at a rate of 10%, payable on April 1, 2024 and on maturity. The company is actively working to raise equity and/or debt to repay these now-expired convertible debentures. The principal amount of the 2024 Debentures is convertible at the option of the holder at \$0.07, and any accrued interest on any principal converted will be concurrently paid in common shares at a deemed price per share, which is determined as the greater of the most recent closing price for the common shares preceding the date of conversion and \$0.05.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

9. CONVERTIBLE DEBENTURES (continued)

The following is a continuity of the convertible debentures:

	December 31,]	March 31,
		2024		2024
Balance, beginning of period / year	\$	794,287	\$	803,000
Issue of 2023 Debentures and 2024 Debentures		-		$1,641,822^{1}$
Equity component		-		(63,974)
Redemptions		(2,000)	(1	$,617,440)^{1}$
Accretion of convertible debentures		33,095		30,879
Balance, end of period / year	\$	825,382	\$	794,287

⁽¹⁾ See description of convertible debenture transactions above. The Company issued 2024 Debentures of \$827,382 to replace 2023 Debentures of \$814,440 and interest of \$12,942. No cash proceeds received or used in relation to the issuance or redemption of convertible debentures during the period.

10. LOANS PAYABLE

	December 31, 2024	March 31, 2024
BDC Loans payable	\$ 1,720	\$ 5,590
Other loans and advances	892,813	666,563
CEBA Loans	80,000	80,000
Total loans payable	974,533	752,153
Loans payable – current	(974,533)	(751,723)
Loans payable – non-current	\$ -	\$ 430

The BDC Loans, acquired through the acquisition of Score-Up in 2019, bear interest at 8.05% per annum, require monthly payments inclusive of principal and interest, and mature on May 10, 2023, and October 10, 2024. During the nine months ended December 31, 2024, the Company made aggregate payments on the BDC Loans in the amount of \$4,339 inclusive of interest and administration fees of \$469.

As at December 31, 2024, the Company owed an aggregate of \$Nil principal amount of loans to related parties (March 31, 2024 - \$Nil). As at December 31, 2024, the Company owed an aggregate of \$727,813 (March 31, 2024 - \$666,563) of loans to a company controlled by a significant shareholder (>10%) which bear interest at a rate of 12% per annum and have no fixed terms of repayment.

During the year ended December 31, 2020, the Company received a \$40,000 Canada Emergency Business Account loan (the "CEBA Loan"). The CEBA Loan carries interest at 5% per annum with full principal repayment due on December 31, 2026. As part of the acquisition of Inverite Verification, the Company acquired an additional \$40,000 of CEBA loans under the same repayment terms as the CEBA Loan.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

11. BONDS

Effective April 6, 2023, Inverite entered into bond assumption and assignment agreements with TPF such that Inverite assumed all of the obligations related to the bond and interest payables pursuant to TPF bonds outstanding as at April 6, 2023. Effective April 6, 2023, Inverite also entered into debt settlement agreements ("Debt Settlement Agreements") with each of the holders of the bonds outstanding in order to complete the bond restructuring transaction to settle an aggregate of \$5,775,220 of bond and interest debt (the "Bond Debt Restructuring"). Pursuant to the Debt Settlement Agreements, bondholders agreed to settle their bond and accrued interest amounts outstanding through a combination of shares for debt, debt forgiveness and/or waiver of interest expense accrued from Q1 2022 to April 6, 2023.

On April 6, 2023, Inverite closed the first tranche of the Bond Debt Restructuring with certain bondholders. Inverite settled an aggregate of \$4,150,544 of bonds payable and accrued interest payable outstanding through a combination of shares for debt (\$3,210,872 settled through issuance of 33,644,957 shares), debt forgiveness (\$460,873) and waiver of interest (\$478,799). As a result, Inverite recorded a gain on debt settlement of \$1,795,396.

On May 16, 2023, Inverite closed the second and final tranche of the Bond Debt Restructuring with the remaining bondholders. Inverite settled an aggregate of \$1,624,676 of bonds payable and accrued interest payable outstanding through a combination of shares for debt (\$858,543 settled through issuance of 10,653,893 shares), debt forgiveness (\$620,543) and waiver of interest (\$145,590). As a result, Inverite recorded an aggregate gain on debt settlement of \$1,145,252. As a result of the two closings, the Company eliminated all of its bond debt and bond interest obligations.

12. SHARE CAPITAL

Authorized share capital

- An unlimited number of common shares without par value.
- An unlimited number of non-voting shares without par value.
- An unlimited number of special shares without par value.

Issued share capital

As at December 31, 2024, Inverite had 213,947,940 (March 31, 2024 – 196,499,369) common shares issued and outstanding. No non-voting shares and no special shares are issued and outstanding.

During the nine months ended December 31, 2024, Inverite completed the following share issuances:

- a) Inverite issued a total of 15,820,000 \$0.05 Units inclusive of finder's fee shares, for proceeds of \$791,000 less finder's fees of \$15,400 through non-brokered private placements.
- b) Inverite issued a total of 1,600,000 common shares pursuant to the vesting of restricted share units. An aggregate of \$77,500 was transferred from reserves to share capital.
- c) Inverite issued 28,571 common shares for the redemption of \$2,000 convertible debenture at a price of \$0.07.

During the period ended March 31, 2024, Inverite completed the following share issuances:

- a) Inverite issued a total of 12,913,300 \$0.05 Units inclusive of finder's fee shares, for proceeds of \$625,330 through non-brokered private placements.
- b) Inverite issued a total of 11,121,670 \$0.07 Units inclusive of finder's fee shares, for proceeds of \$731,570 through non-brokered private placements.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

12. SHARE CAPITAL (continued)

- c) Inverite issued a total of 44,298,850 common shares to settle \$4,069,415 of bond and accrued interest payables as a part of the Bond Debt Restructuring transaction involving TPF and the holders of TPF bonds.
- d) Inverite issued a total of 600,000 common shares pursuant to the vesting of restricted share units. An aggregate of \$49,500 was transferred from reserves to share capital.
- e) Inverite issued 600,000 common shares in exchange for the exercise of 600,000 options, each having an exercise price of \$0.05.
- f) Inverite issued 2,907,011 common shares at a deemed price of \$0.235 per share in satisfaction of the year two earnout provision related to the acquisition of Inverite Verification (see Note 4).
- g) Inverite issued 1,835,893 common shares at a fair market value of \$0.05 per share in exchange for settling a total of \$102,275 in accounts payable.
- h) Inverite issued 714,027 common shares at a fair market value of \$42,842 to settle \$35,701 of accrued interest payable pursuant to the 2023 Debentures (see Note 9).

Shares Issuable

On January 22, 2021, Inverite launched a 12-month online marketing campaign through AGORACOM Internet Relations Corp. The total cost of the campaign was \$75,000 plus applicable taxes, payable through the issuance of common shares with the first 20% of the fee payable on the commencement date and 20% at the end of each of the third, sixth, ninth and twelfth months thereafter. Inverite issued 40,843 common shares on January 27, 2021 from treasury, for the first installment of the fee plus applicable taxes. The fair value of the 40,843 common shares was determined to be \$15,000 plus tax. As at December 31, 2024, Inverite had not issued shares representing the fees payable for the second, third, fourth and fifth installments. As a result, Inverite has recorded \$67,800 of shares issuable.

Omnibus Equity Incentive Plan

The Company has a share purchase option plan (the "Share Purchase Option Plan") under which it is authorized to grant options for the acquisition of its common shares to directors, employees and consultants up to a maximum of 10% of the issued and outstanding common shares of Inverite at the time the plan was adopted. The exercise price shall not be less than the market price of Inverite's common shares as at the grant date and in accordance with CSE policies. The options may be granted for a maximum term of five years. Options granted to directors, employees and consultants, other than consultants engaged in investor relations activities, will generally be subject to standard vesting provisions as to 25% on the date of grant and 25% on each anniversary date, such that all share purchase options fully vest over three years from the date of grant, unless otherwise determined by Inverite's Board of Directors. Share purchase options granted to consultants engaged in investor relations activities will vest in stages over a minimum period of twelve months, pursuant to the Share Purchase Option Plan and as determined by Inverite's Board of Directors.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

12. SHARE CAPITAL (continued)

Omnibus Equity Incentive Plan (continued)

During the nine months ended December 31, 2024, Inverite granted and aggregate of 5,100,000 share purchase options (December 31,2023-3,675,000). The weighted average fair value of the options granted during the nine month period ended December 31,2024, was approximately 0.03 per option (December 31,2023-0.04). The fair value was estimated using the Black-Scholes option pricing model using the following weighted average inputs:

	December 31, 2024	March 31 2024
Risk-free interest rate	4.10%	3.9%
Expected volatility	111%	102%
Expected dividends	0%	0%
Expected life	2.5 years	2.4 years
Grant date share price	\$ 0.05 \$	0.06
Exercise price	\$ 0.05 \$	0.06

Expected volatility was determined based on the historical volatility of Inverite's shares over a period commensurate with the expected option life. The expected option life incorporates an estimate of early exercise.

For the nine months ended December 31, 2024, Inverite recognized \$164,709 (December 31, 2023 - \$125,827) as net share-based payments for options vesting during the period.

A summary of share purchase option activity is as follows:

	Number of share purchase options	Weighted Exerc	Average ise Price
Balance, December 31, 2022	8,925,000	\$	0.15
Granted	7,845,000		0.06
Exercised	(600,000)		0.05
Expired / Cancelled / Forfeited	(2,625,000)		0.16
Balance, March 31, 2024	13,545,000	\$	0.10
Granted	5,100,000		0.05
Expired / Cancelled / Forfeited	(4,200,000)		0.14
Balance, December 31, 2024	14,445,000	\$	0.07
Exercisable, December 31, 2024	7,411,250	\$	0.08

The weighted average remaining contractual life of the options outstanding as at December 31, 2024 is 3.35 years.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

12. SHARE CAPITAL (continued)

Omnibus Equity Incentive Plan (continued)

Details of share purchase options outstanding as at December 31, 2024 are as follows:

			Number	Number
Expiry Date	Exe	rcise Price	Outstanding	Exercisable
January 23, 2025	\$	0.20	100,000	100,000
March 2, 2025	\$	0.19	100,000	100,000
March 31, 2025	\$	0.10	500,000	375,000
March 31, 2025	\$	0.055	1,310,000	327,500
April 28, 2027	\$	0.13	1,100,000	950,000
July 29, 2027	\$	0.09	50,000	37,500
October 18, 2027	\$	0.10	1,000,000	1,000,000
October 31, 2027	\$	0.10	600,000	450,000
January 31, 2028	\$	0.08	100,000	50,000
April 25, 2028	\$	0.08	200,000	100,000
December 7, 2028	\$	0.05	1,600,000	1,600,000
February 15, 2029	\$	0.055	2,685,000	671,250
April 30, 2029	\$	0.05	4,000,000	1,000,000
May 13, 2029	\$	0.05	600,000	150,000
October 31, 2029	\$	0.05	500,000	500,000
			14,445,000	7,411,250

Warrants

As at December 31, 2024, an aggregate of 44,028,317 common share purchase warrants are outstanding. A summary of the warrant activity is as follows:

		Weighted
	Number of	Average
	warrants	Exercise Price
Balance, December 31, 2022	15,360,205	0.14
Granted	17,732,100	0.10
Expired / Cancelled	(4,883,988)	0.20
Balance, March 31, 2024	28,208,317	\$ 0.11
Granted	15,820,000	0.10
Expired / Cancelled	(10,476,217)	0.11
Balance, December 31, 2024	33,552,100	\$ 0.10

The weighted average remaining contractual life of the warrants outstanding as at December 31, 2024 is 1.18 years.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

12. SHARE CAPITAL (continued)

Details of common share purchase warrants and finder warrants outstanding as at December 31, 2024 are as follows:

	_		Number
Expiry Date	Exe	ercise Price	Outstanding
		0.44	
January 3, 2025	\$	0.11	393,000
January 23, 2025	\$	0.11	430,00
March 13, 2025	\$	0.11	835,00
March 30, 2025	\$	0.11	430,00
April 27, 2025	\$	0.11	714,50
June 13, 2025	\$	0.11	429,00
July 12, 2025	\$	0.11	414,50
July 27, 2025	\$	0.11	400,00
August 11, 2025	\$	0.11	429,00
August 29, 2025	\$	0.11	357,50
September 13, 2025	\$	0.11	393,00
September 27, 2025	\$	0.10	1,100,00
November 10, 2025	\$	0.10	1,100,00
December 28, 2025	\$	0.10	550,00
February 6, 2026	\$	0.10	1,960,00
February 16, 2026	\$	0.10	4,400,00
March 11, 2026	\$	0.10	2,596,60
March 26, 2026	\$	0.10	800,00
April 23, 2026	\$	0.10	1,020,00
May 9, 2026	\$	0.10	1,100,00
May 27, 2026	\$	0.10	1,700,00
June 27, 2026	\$	0.10	1,100,00
July 9, 2026	\$	0.10	2,700,00
July 25, 2026	\$	0.10	6,000,00
September 10, 2026	\$	0.10	1,100,00
October 9, 2026	\$	0.10	1,100,00
			33,552,10

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

12. SHARE CAPITAL (continued)

Restricted Share Units

During the period ended December 31, 2023, the Company adopted a long-term restricted share unit plan (the "RSU Plan"). The restricted share units ("RSUs") entitle directors, officers, consultants or employees to acquire common shares of the Company, based on vesting provisions determined by Marble's Board of Directors at the time of grant.

During the nine months ended December 31, 2024, Marble granted 3,200,000 RSUs.

- On April 1, 2024 the Company granted 400,000 RSUs to a consultant. 25% of the RSUs vest on each of June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025.
- On April 24, 2024 the Company granted 400,000 RSUs to a consultant. 25% of the RSUs vest on each of June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025.
- On April 30, 2024 the Company granted 2,000,000 RSUs to a director of the Company. 25% of the RSUs vest on each of July 31, 2024, October 31, 2024, January 31, 2025 and April 30, 2025.
- On May 13, 2024 the Company granted 400,000 RSUs to a consultant. 25% of the RSUs vest on each of August 13, 2024, November 13, 2024, February 13, 2025 and May 13, 2025.

During the period ended March 31, 2024, Inverite granted 1,400,000 RSUs.

- On April 1, 2023 the Company granted 400,000 RSUs to a consultant. 25% of the RSUs vest on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2024.
- On April 28, 2023, the Company granted an aggregate of 1,000,000 RSUs to consultants which vest as
 up to 25% of the RSUs on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2024,
 subject to meeting other performance based vesting criteria. 1,000,000 of these RSUs were cancelled
 during the period.

During the nine months ended December 31, 2024, Marble recognized \$134,920 as share-based payments related to RSUs (December 31, 2023 - \$25,544). As at December 31, 2024, 1,700,000 RSUs are outstanding (March 31, 2024 – 100,000).

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

12. SHARE CAPITAL (continued)

Performance Share Units

During the period ended December 31, 2024, the Company adopted a long-term performance share unit plan (the "PSU Plan"). The PSU entitle directors, officers, consultants or employees to acquire common shares of the Company, based on vesting provisions determined by Inverite's Board of Directors at the time of grant.

During the nine months ended December 31, 2024, Inverite granted 1,050,000 PSUs.

On April 1, 2024 the Company granted 1,050,000 PSUs to a consultant. 25% of the PSUs vest on each
of June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025 if certain criteria were
met.

During the nine months ended December 31, 2024, Inverite recognized \$47,993 as share-based payments related to PSUs (September 30, 2023 - \$Nil). As at December 31, 2024, 825,000 PSUs are outstanding (March 31, 2024 - Nil).

13. RELATED PARTY TRANSACTIONS

Related parties of the Company include key management personnel, companies controlled by key management personnel and close family members of key management personnel. Key management personnel are persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any directors (whether executive or otherwise) of the Company. Key management personnel are composed of the board of directors and executive leadership team.

Compensation

Salaries paid to the Company's key management personnel for the three and nine-month periods ended December 31, 2024 totalled \$104,000 and \$312,000 respectively (2023 - \$104,000 and \$312,000).

Consulting fees

Consulting fees paid to the Company's key management personnel and companies controlled by key management personnel for the three and nine month periods ended December 31, 2024 totalled \$66,000 and \$198,000 respectively (2023 – \$48,350 and \$180,550). As at December 31, 2024, accounts payable included an aggregate of \$334,625 (March 31, 2024- \$326,748) owing to key management personnel and companies controlled by key management personnel.

Omnibus Equity Incentive plan

Included in the share-based payments for the three- and nine-month periods ended December 31, 2024 is \$62,810 and \$199,520 respectively (2023 - \$56,815 and \$79,753) related to the fair value of share purchase options and/or RSUs vested for key management personnel.

Loans and Other Transactions

As at December 31, 2024, loans payable included an aggregate of \$Nil (March 31, 2024 - \$Nil) loans received from directors of the Company and a company controlled by a director. The loans bear interest at a rate of 12% per annum and have no fixed terms of repayment.

During the three and nine month periods ended December 31, 2024, the Company incurred an aggregate of \$Nil and \$ (2023 - \$1,966 and \$5,876) of interest expense pursuant to loans held by directors of the Company and a company controlled by a director.

Notes to the Condensed Consolidated Interim Financial Statements For the nine months ended December 31, 2024 and 2023 (Unaudited – Presented in Canadian Dollars)

14. CAPITAL RISK MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern, to provide our solutions to benefit our customers and clients, to provide returns to shareholders and benefits to our stakeholders, and to maintain a flexible capital structure which optimizes the cost of capital to an acceptable risk. The Company considers its capital for this purpose to be its shareholders' deficiency, convertible debentures and loans. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure and the amount of cash, the Company may issue common shares or debt or acquire or dispose of assets. In order to facilitate the management of its capital requirements, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

15. SUPPLEMENTAL CASH FLOW INFORMATION

For the Nine-month period ended	December 31, 2024	December 31, 2023
Redemption of convertible debentures	2,000	-
RSUs issued	77,500	-

16. EVENTS AFTER THE REPORTING PERIOD

On January 9, 2025, Inverite issued an aggregate of 300,000 common shares pursuant to the vesting of RSU. An aggregate of \$15,000 was transferred from reserves to share capital as a result.

On January 16, 2025, Inverite issued 3,675,000 stock options to directors and employees under the company's omnibus equity incentive plan. The stock options have a strike price of \$0.05 and have a term of 5 years.

On January 17, 2025, Inverite issued 1,600,000 \$0.05 Units for proceeds of \$80,000 pursuant to a non-brokered private placement.

January 31, 2025 – Inverite issued an aggregate of 500,000 common shares pursuant to the vesting of RSU. An aggregate of \$22,500 was transferred from reserves to share capital as a result.

February 11, 2025 – Inverite issued 1,000,000 \$0.05 Units for proceeds of \$50,000 pursuant to a non-brokered private placement.

February 13, 2025 – Inverite issued an aggregate of 100,000 common shares pursuant to the vesting of RSU. An aggregate of \$5,000 was transferred from reserves to share capital as a result.

February 14, 2025 – Inverite issued 1,200,000 \$0.05 Units for proceeds of \$60,000 pursuant to a non-brokered private placement.